Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

48.11
Delayed Data
As of Nov 17
 -0.11 / -0.23%
Today’s Change
44.02
Today|||52-Week Range
91.35
-31.57%
Year-to-Date

Today’s Trading

Previous close48.22
Today’s open47.90
Day’s range46.35 - 49.27
Volume549,091
Average volume (3 months)353,970
Market cap$2.0B
Dividend yield--
Data as of 4:00pm ET, 11/17/2017

Growth & Valuation

Earnings growth (last year)-56.82%
Earnings growth (this year)-17.26%
Earnings growth (next 5 years)+26.36%
Revenue growth (last year)--
P/E ratioNM
Price/Sales20,927.50
Price/Book4.19

Competitors

 Today’s
change
Today’s
% change
IRWDIronwood Pharmaceuti...+0.42+2.78%
LOXOLoxo Oncology Inc+0.16+0.21%
FOLDAmicus Therapeutics ...-0.37-2.74%
SUPNSupernus Pharmaceuti...+0.10+0.26%
Data as of 4:00pm ET, 11/17/2017

Financials

Next reporting dateMarch 28, 2018
EPS forecast (this quarter)-$1.92
Annual revenue (last year)$133.0K
Annual profit (last year)-$245.9M
Net profit margin-184,867.67%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Emil D. Kakkis
Chief Financial Officer &
Executive Vice President
Shalini Sharp
Corporate headquarters
Novato, California

Forecasts